MX2014001945A - Procedimiento e intermedios para la preparacion de macrolactamas. - Google Patents

Procedimiento e intermedios para la preparacion de macrolactamas.

Info

Publication number
MX2014001945A
MX2014001945A MX2014001945A MX2014001945A MX2014001945A MX 2014001945 A MX2014001945 A MX 2014001945A MX 2014001945 A MX2014001945 A MX 2014001945A MX 2014001945 A MX2014001945 A MX 2014001945A MX 2014001945 A MX2014001945 A MX 2014001945A
Authority
MX
Mexico
Prior art keywords
intermediates
macrolactams
preparing
methods
compounds
Prior art date
Application number
MX2014001945A
Other languages
English (en)
Spanish (es)
Inventor
Tao Wang
Feng Xu
Laura Artino
Guy Humphrey
Tao Pei
Zhiguo Jake Song
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2014001945A publication Critical patent/MX2014001945A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/04Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a three or four-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/32Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/14Preparation of carboxylic acid esters from carboxylic acid halides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12Acetic acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2014001945A 2011-08-19 2012-08-16 Procedimiento e intermedios para la preparacion de macrolactamas. MX2014001945A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161525462P 2011-08-19 2011-08-19
US201161533439P 2011-09-12 2011-09-12
US201161533915P 2011-09-13 2011-09-13
US201161539540P 2011-09-27 2011-09-27
PCT/US2012/051177 WO2013028470A1 (en) 2011-08-19 2012-08-16 Process and intermediates for preparing macrolactams

Publications (1)

Publication Number Publication Date
MX2014001945A true MX2014001945A (es) 2014-03-27

Family

ID=47746773

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014001945A MX2014001945A (es) 2011-08-19 2012-08-16 Procedimiento e intermedios para la preparacion de macrolactamas.
MX2014001944A MX2014001944A (es) 2011-08-19 2012-08-16 Formas cristalinas de un inhibidor de la proteasa del virus de la hepatitis c.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014001944A MX2014001944A (es) 2011-08-19 2012-08-16 Formas cristalinas de un inhibidor de la proteasa del virus de la hepatitis c.

Country Status (11)

Country Link
US (3) US9242917B2 (enExample)
EP (3) EP2744331A4 (enExample)
JP (2) JP2014521750A (enExample)
KR (2) KR20140059236A (enExample)
CN (2) CN103889439A (enExample)
AU (2) AU2012299218A1 (enExample)
BR (2) BR112014003802A2 (enExample)
CA (2) CA2844386A1 (enExample)
MX (2) MX2014001945A (enExample)
RU (2) RU2014110399A (enExample)
WO (3) WO2013028465A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112014003802A2 (pt) 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
HRP20161694T1 (hr) 2012-10-19 2017-03-10 Bristol-Myers Squibb Company 9-metil supstituirani heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4) diazaciklopentadecinil karbamat derivati kao ne-strukturalni 3 (ns3) proteazni inhibitori za liječenje infekcija virusom hepatitisa c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
WO2015057611A1 (en) * 2013-10-18 2015-04-23 Merck Sharp & Dohme Corp. Methods and intermediates for preparing macrolactams
WO2015095437A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Methods and intermediates for the preparation of macrolactams
PT3636649T (pt) * 2014-01-24 2024-04-09 Turning Point Therapeutics Inc Diaril macrociclos como moduladores das proteínas quinases
CA2948902C (en) 2014-06-06 2022-11-22 Abbvie Inc. Crystal forms of hcv protease inhibitors and use thereof
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
FI3319969T3 (fi) * 2015-07-06 2024-06-13 Turning Point Therapeutics Inc Diaryylimakrosyklipolymorfi
RS66238B1 (sr) * 2015-07-21 2024-12-31 Turning Point Therapeutics Inc Hiralni diaril makrocikl i njegova primena u lečenju karcinoma
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
HRP20221502T1 (hr) 2017-12-19 2023-03-31 Turning Point Therapeutics, Inc. Makrociklički spojevi za liječenje bolesti
CN111057045A (zh) * 2019-12-18 2020-04-24 安徽红杉生物医药科技有限公司 Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871868A (en) 1987-03-11 1989-10-03 Takeda Chemical Industries, Ltd. Production of substituted acetylenic compounds
GB9207987D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Novel container and closure
US5716960A (en) * 1995-01-13 1998-02-10 U.S. Bioscience Inc. And Individuals Crystalline trimetrexate salts and the process for making the same
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
ZA98879B (en) * 1997-02-04 1998-08-03 Ono Pharmaceutical Co Omega-cycloalkyl-prostaglandin e2 derivatives
CN101119991B (zh) * 2005-02-18 2012-01-25 田边三菱制药株式会社 脯氨酸衍生物的盐,其溶剂合物,及其生产方法
US7834145B2 (en) 2005-03-22 2010-11-16 Merck Sharp & Dohme Corp. HCV protease substrates
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
UA90909C2 (en) * 2005-07-20 2010-06-10 Мерк Шарп Энд Домэ Корп. Hcv ns3 protease inhibitors
AU2006275605B2 (en) 2005-08-01 2011-01-06 Merck Sharp & Dohme Corp. Macrocyclic peptides as HCV NS3 protease inhibitors
JP2009527546A (ja) 2006-03-07 2009-07-30 ザ プロクター アンド ギャンブル カンパニー ケラチン繊維を酸化染色するための組成物、及び前記組成物の使用法
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
CA2667266C (en) 2006-10-24 2015-11-24 Merck & Co., Inc. Hcv ns3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
EP2086982B1 (en) * 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CN101784549A (zh) 2007-05-03 2010-07-21 因特蒙公司 丙型肝炎病毒复制的新颖大环抑制剂
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
CA2714604A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Macrocyclic hcv ns3 protease inhibitors
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
SI2310095T1 (sl) * 2008-07-22 2013-01-31 Merck Sharp & Dohme Corp. Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
AU2010286681A1 (en) * 2009-08-27 2012-02-09 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
BR112014003802A2 (pt) 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento

Also Published As

Publication number Publication date
EP2744336A4 (en) 2014-12-31
BR112014003798A2 (pt) 2017-03-01
US20140243519A1 (en) 2014-08-28
EP2744336B1 (en) 2017-07-05
RU2014110399A (ru) 2015-09-27
AU2012299218A1 (en) 2014-02-20
WO2013028465A1 (en) 2013-02-28
EP2744336A1 (en) 2014-06-25
EP2744507A4 (en) 2015-01-28
WO2013028471A1 (en) 2013-02-28
CA2844386A1 (en) 2013-02-28
CA2844388A1 (en) 2013-02-28
AU2012299223A1 (en) 2014-02-27
US20140206605A1 (en) 2014-07-24
CN103874414A (zh) 2014-06-18
US9242917B2 (en) 2016-01-26
US9238604B2 (en) 2016-01-19
EP2744507A1 (en) 2014-06-25
EP2744331A1 (en) 2014-06-25
MX2014001944A (es) 2014-03-27
KR20140059236A (ko) 2014-05-15
WO2013028470A1 (en) 2013-02-28
KR20140053330A (ko) 2014-05-07
US20140200343A1 (en) 2014-07-17
JP2014521750A (ja) 2014-08-28
US9073825B2 (en) 2015-07-07
CN103889439A (zh) 2014-06-25
EP2744331A4 (en) 2015-01-21
RU2014110400A (ru) 2015-09-27
JP2014524442A (ja) 2014-09-22
BR112014003802A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2014001945A (es) Procedimiento e intermedios para la preparacion de macrolactamas.
MY201670A (en) Condensed imidazolylimidazoles as antiviral compounds
WO2012082672A3 (en) Process and intermediates for preparing macrolactams
MX2020001602A (es) Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
MX2014013660A (es) Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b.
TW201240990A (en) Antiviral compounds
MX359032B (es) Inhibidores de pirrolopirazina cinasa.
SG176015A1 (en) Antiviral compounds
NZ749557A (en) 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
PH12015500376A1 (en) Novel bicyclic pyridinones
MX2011011272A (es) Procesos e intermediarios.
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
MX2013015147A (es) Procesos y compuestos intermediarios para producir azaindoles.
MY192466A (en) Processes for the preparation of an apoptosis-inducing agent
MY170618A (en) Macrocyclic compounds and methods for their production
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
IN2014KN01062A (enExample)
IN2014KN02722A (enExample)
MX2013012771A (es) Proceso para la preparacion de inhibidores del virus de la hepatitis c.
MX337610B (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
WO2015095437A8 (en) Methods and intermediates for the preparation of macrolactams
NZ725365A (en) Antiviral compounds inhibitors of hcv ns5b
IN2012DE00693A (enExample)